The mechanism of these endocannabinoid-targeting drugs varies based on the type of cancer and the receptor, CBR-1, CBR-2, transient receptor potential vanilloid TRPV1 or TRPV2, and whether it is dependent or independent. Here, TRPV2 is linked to cancer.